Data from: Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

负责人：

关键词：

Multiple Sclerosis;biomarker;Clinical Trials;Neuromyelitis optica spectrum disorders;Observational study (Cohort Case control);Demyelinating disease (CNS)

DOI：

doi:10.5061/dryad.dp75314

摘要：

) (n = 49; 49 serum samples), patients with NMOSD (n = 33; 42 CSF and 102 serum samples), and patients with multiple sclerosis (MS) (n = 49; 53 CSF and 91

Data from: Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice

负责人：

关键词：

Multiple Sclerosis;Clinical Trials

DOI：

doi:10.5061/dryad.n0cg254

摘要：

) treatment in patients with multiple sclerosis. Methods: Using peripheral blood from several clinical trials of DMF, immune cell subsets were quantified usi

Data from: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

负责人：

关键词：

Neuromyelitis Optica;prevalence;criteria;AQP4-antibody;Incidence;NMOSD;population-based

DOI：

doi:10.5061/dryad.369417f

摘要：

prospective study. Data were sourced from the Danish National Patient Registry, the Danish Multiple Sclerosis Registry, departments of neurology and laboratories

Data from: The prevalence of MS in the United States: a population-based estimate using health claims data

负责人：

关键词：

DOI：

doi:10.5061/dryad.pm793v8

摘要：

Objective: To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple

Data from: A new way to estimate neurologic disease prevalence in the United States

负责人：

关键词：

DOI：

doi:10.5061/dryad.t1k42p8

摘要：

Objective: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis